Medicare Enrolled
Dr. Suzy Melkonian, MD
Medical Oncology · Chatsworth, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Melkonian from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Melkonian?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Melkonian
Dr. Suzy Melkonian is a medical oncology specialist in Chatsworth, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Melkonian performed 15,805 Medicare services across 338 unique beneficiaries.
Between the years covered by Open Payments, Dr. Melkonian received a total of $19,334 from 72 pharmaceutical and/or device companies across 910 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Melkonian is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 17% volume in CA
$19,334 industry payments
Medicare Practice Summary
Medicare Utilization ↗15,805
Medicare services
Top 17% in CA for medical oncology
338
Unique beneficiaries
$4
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~790 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
12,750 | $1 | $3 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
944 | $0 | $1 |
| Injection, granisetron hydrochloride, 100 mcg | 935 | $0 | $1 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
271 | $26 | $61 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
171 | $18 | $42 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
100 | $104 | $231 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
99 | $12 | $48 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
99 | $1 | $2 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
94 | $119 | $494 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
94 | $78 | $158 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
90 | $14 | $39 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
63 | $25 | $60 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
55 | $56 | $157 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
40 | $151 | $308 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
84.4% high complexity
14.1% medium
1.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$19,334
Total received (2018-2024)
Avg $2,762/year across 7 years
Top 31% in CA for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
72
Companies
910
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$17,765 (91.9%)
Other
Charitable contributions, space rental, and other categories
$1,199 (6.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$369 (1.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,054
2023
$3,601
2022
$3,055
2021
$3,616
2020
$1,987
2019
$2,722
2018
$2,299
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Gilead Sciences, Inc.
$267
Daiichi Sankyo Inc.
$231
AstraZeneca Pharmaceuticals LP
$145
Incyte Corporation
$138
Novartis Pharmaceuticals Corporation
$137
PFIZER INC.
$125
GENZYME CORPORATION
$119
Lilly USA, LLC
$83
Celgene Corporation
$68
Regeneron Healthcare Solutions, Inc.
$60
E.R. Squibb & Sons, L.L.C.
$54
Karyopharm Therapeutics Inc.
$52
Eisai Inc.
$52
Adaptive Biotechnologies Corporation
$51
Merck Sharp & Dohme LLC
$50
Astellas Pharma US Inc
$45
PharmaEssentia USA Corporation
$43
Bayer Healthcare Pharmaceuticals Inc.
$34
SUN PHARMACEUTICAL INDUSTRIES INC.
$34
ABBVIE INC.
$30
Myriad Genetic Laboratories, Inc.
$29
Immunocore Limited
$28
TAIHO ONCOLOGY, INC.
$27
PUMA BIOTECHNOLOGY, INC.
$27
Rigel Pharmaceuticals, Inc.
$27
ARRAY BIOPHARMA INC
$24
Janssen Biotech, Inc.
$21
EMD Serono, Inc.
$21
Octapharma USA, Inc.
$20
Takeda Pharmaceuticals U.S.A., Inc.
$14
Top 3 companies account for 31.3% of 2024 payments
All-time payments by company (2018-2024) ›
GENZYME CORPORATION
$1,770
Novartis Pharmaceuticals Corporation
$1,607
E.R. Squibb & Sons, L.L.C.
$1,590
Amgen Inc.
$1,175
Incyte Corporation
$1,156
PFIZER INC.
$971
Merck Sharp & Dohme Corporation
$757
Genentech USA, Inc.
$707
AstraZeneca Pharmaceuticals LP
$700
Seagen Inc.
$577
Takeda Pharmaceuticals U.S.A., Inc.
$572
Lilly USA, LLC
$568
Karyopharm Therapeutics Inc.
$541
Daiichi Sankyo Inc.
$448
Celgene Corporation
$432
Gilead Sciences, Inc.
$394
Merck Sharp & Dohme LLC
$361
GlaxoSmithKline, LLC.
$300
Eisai Inc.
$280
SANOFI-AVENTIS U.S. LLC
$274
Boehringer Ingelheim Pharmaceuticals, Inc.
$265
NOVARTIS PHARMACEUTICALS CORPORATION
$250
Janssen Biotech, Inc.
$245
Puma Biotechnology, Inc.
$244
EISAI INC.
$206
Astellas Pharma US Inc
$204
Seattle Genetics, Inc.
$182
Regeneron Healthcare Solutions, Inc.
$170
BeiGene USA, Inc.
$168
TESARO, Inc.
$140
TerSera Therapeutics LLC
$119
Bayer HealthCare Pharmaceuticals Inc.
$114
Bayer Healthcare Pharmaceuticals Inc.
$106
Intuitive Surgical, Inc.
$96
Octapharma USA, Inc.
$85
Mirati Therapeutics, Inc.
$81
ADC Therapeutics America, Inc.
$78
Clovis Oncology, Inc.
$73
Alexion Pharmaceuticals, Inc.
$71
Myriad Genetic Laboratories, Inc.
$71
PUMA BIOTECHNOLOGY, INC.
$67
EMD Serono, Inc.
$63
PharmaEssentia USA Corporation
$63
MorphoSys, US Inc.
$60
TAIHO ONCOLOGY, INC.
$60
Rigel Pharmaceuticals, Inc.
$59
Boston Scientific Corporation
$59
INSYS Therapeutics Inc
$52
Adaptive Biotechnologies Corporation
$51
Dova Pharmaceuticals
$45
Pharmacyclics LLC, an AbbVie Company
$44
BOSTON SCIENTIFIC CORPORATION
$42
Foundation Medicine, Inc.
$41
AbbVie, Inc.
$39
Genentech, Inc.
$38
Advanced Accelerator Applications
$36
West Therapeutics Development, LLC
$34
SUN PHARMACEUTICAL INDUSTRIES INC.
$34
ABBVIE INC.
$30
Immunocore Limited
$28
Coherus Biosciences Inc.
$27
ARRAY BIOPHARMA INC
$24
Taiho Oncology, Inc.
$24
Global Blood Therapeutics, Inc.
$23
Mylan Institutional Inc.
$22
Lexicon Pharmaceuticals, Inc.
$21
Blueprint Medicines Corporation
$20
Pharmacyclics LLC, An AbbVie Company
$20
Janssen Pharmaceuticals, Inc
$19
MEDIVATION FIELD SOLUTIONS LLC
$16
Tactile Systems Technology Inc
$13
Chiesi USA, Inc.
$13
Top 3 companies account for 25.7% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · ANGIOJET · AYVAKIT · Alecensa · Avastin · BAVENCIO · BESREMI · BOSULIF · BRUKINSA · Blincyto · CABLIVI · CALQUENCE · CAMZYOS · CUTAQUIG · CYRAMZA · Creon · DARZALEX · Da Vinci Surgical System · Doptelet · EKOSONIC · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ERBITUX · ERLEADA · EkoSonic · Enhertu · Erleada · FERRIPROX · FLEXITOUCH · FOUNDATIONONE · Fabhalta · GAZYVA · GILOTRIF · General - Balloons · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LENVIMA · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lutathera · MEKINIST · MONJUVI · MVASI · MYRISK · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · Ogivri · PANZYGA · PEMAZYRE · PIQRAY · PROMACTA · Perjeta · Pomalyst · Prolia · REBLOZYL · RYBREVANT · RYDAPT · Revlimid · Rezlidhia · Rubraca · SARCLISA · SPRYCEL · SUBSYS · SUTENT · SYNDROS · Stivarga · Subsys · TAFINLAR · TAGRISSO · TALZENNA · TASIGNA · TECENTRIQ · TEPMETKO · TIVDAK · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Trodelvy · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · Venclexta · XALKORI · XARELTO · XPOVIO · XTANDI · Xermelo · Xospata · Xtandi · YONSA · ZEJULA · ZEPOSIA · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (92%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
27
Per 100K population
0.3
County median income
$87,760
Nearest hospital
NORTHRIDGE HOSPITAL MEDICAL CENTER
6.2 mi
6.2 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Melkonian is a mixed practice specialist, with above-average Medicare volume (top 17% in CA), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Melkonian experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Melkonian performed 12,750 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Melkonian receive payments from pharmaceutical companies?
Yes. Dr. Melkonian received a total of $19,334 from 72 companies across 910 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Melkonian's costs compare to other medical oncologists in Chatsworth?
Dr. Melkonian's average Medicare payment per service is $4. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Melkonian) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Chatsworth
Browse medical oncologists in Chatsworth ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in CA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in CA
Which CA medical oncologists receive the most from drug and device companies.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology